Plant Name: Epimedium brevicornu
Taxonomic Information:
Plant ID: NPO4957
Plant Latin Name: Epimedium brevicornu
Taxonomy Genus: Epimedium
Taxonomy Family: Berberidaceae
Plant External Links:
NCBI TaxonomyDB:
253618
Plant-of-the-World-Online:
107262-1
Used in Medicines:
Unknown.
Geographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| BLM; TDP1; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; POLB; | |
| PDE5A; | |
| ACHE; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA12; CA7; CA4; | |
| TYR; | |
| KDM4E; | |
| MMP12; MMP9; MMP1; MMP2; | |
| AHR; HIF1A; NFKB1; | |
| FUT7; | |
| LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 7.949E-07 | 6.182E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.043E-07 | 6.493E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.244E-07 | 6.493E-04 | ALOX12, CDK1, FLT3, HIF1A, IGF1R, KDR, MMP12, MMP2, MMP9, PIM1, TSHR |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.991E-06 | 1.102E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.246E-06 | 1.112E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.405E-06 | 1.577E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.972E-06 | 1.663E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.972E-06 | 1.663E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 8.331E-06 | 3.023E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, KDM4E, NOX4, TYR |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 8.791E-06 | 3.138E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.869E-06 | 3.411E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.190E-05 | 3.868E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.190E-05 | 3.868E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.311E-05 | 4.136E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.311E-05 | 4.136E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.680E-05 | 4.678E-03 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.912E-05 | 5.088E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.377E-05 | 5.901E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 3.463E-05 | 7.466E-03 | AXL, FLT3, IGF1R, KDR, MET |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.624E-05 | 7.737E-03 | AHR, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 3.957E-05 | 7.954E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 4.447E-05 | 8.493E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.188E-05 | 9.574E-03 | CA12, CA4, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 8.066E-07 | 9.921E-05 | FLT3, MMP1, MMP2, HIF1A, MET, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.506E-06 | 1.093E-04 | MMP2, KDR, HIF1A, MMP9, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.665E-06 | 1.093E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.855E-06 | 1.194E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.509E-05 | 5.144E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.443E-05 | 1.067E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 6.942E-05 | 1.067E-03 | MMP1, MMP2, MMP9 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.574E-06 | 1.194E-04 | CA12, CA4, CA7 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.865E-04 | 2.549E-03 | FLT3, PIM1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.658E-04 | 3.269E-03 | PIM1, CYP1B1, MMP9, MET, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.012E-04 | 3.368E-03 | FLT3, MET, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 9.734E-04 | 8.145E-03 | KDR, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.001E-03 | 8.145E-03 | MMP2, PIM1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.880E-04 | 3.977E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.458E-04 | 5.164E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.060E-03 | 8.145E-03 | HIF1A, NFKB1, IGF1R |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; PDE5A; MMP9; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; PDE5A; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| NA: NA | Raynaud's disease | NA | PDE5A; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; PDE5A; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; PDE5A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ACHE; HIF1A; MMP9; MMP2; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; MMP2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | GIST | NA | FLT3; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | PDE5A; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
